Acta Pharmacologica Sinica 2017: 1618–1631
© 2017 CPS and SIMM All rights reserved 1671-4083/17
www.nature.com/aps

Original Article

Hispidulin mediates apoptosis in human renal cell carcinoma by inducing ceramide accumulation

RETRACTED ARTICLE

Hui GAO[1, 2, #], Ming-quan GAO[1, #], Jian-jun PENG[2, *], Mei HAN[1], Kai-li LIU[1], Yan-tao HAN[3, *]

[1]*Department of Pharmacology, School of Pharmacy, Qingdao University, Qingdao 266021, China;* [2]*College of Life Sciences, Chongqing Normal University, Chongqing 401331, China;* [3]*Medical College, Qingdao University, Qingdao 266071, China*

Abstract

Hispidulin, a polyphenolic flavonoid extracted from the traditional Chinese medicinal plant *S involucrata*, exhibits anti-tumor effects in a wide array of human cancer cells, mainly through growth inhibition, apoptosis induction and cell cycle arrest. However, its precise anticancer mechanisms remain unclear. In this study, we investigated the molecular mechanisms that contribute to hispidulin-induced apoptosis of human clear-cell renal cell carcinoma (ccRCC) lines Caki-2 and ACHN. Hispidulin (10, 20 μmol/L) decreased the viability of ccRCC cells in dose- and time-dependent manners without affecting that of normal tubular epithelial cells. Moreover, hispidulin treatment dose-dependently increased the levels of cleaved caspase-8 and caspase-9, but the inhibitors of caspase-8 and caspase-9 only partly abrogated hispidulin-induced apoptosis, suggesting that hispidulin triggered apoptosis via both extrinsic and intrinsic pathways. Moreover, hispidulin treatment significantly inhibited the activity of sphingosine kinase 1 (SphK1) and consequently promoted ceramide accumulation, thus leading to apoptosis of the cancer cells, whereas pretreatment with K6PC-5, an activator of SphK1, or overexpression of SphK1 significantly attenuated the anti-proliferative and pro-apoptotic effects of hispidulin. In addition, hispidulin treatment dose-dependently activated ROS/JNK signaling and led to cell apoptosis. We further demonstrated in Caki-2 xenograft nude mice that injection of hispidulin (20, 40 mg·kg^{-1}·d^{-1}, ip) dose-dependently suppressed tumor growth accompanied by decreased SphK1 activity and increased ceramide accumulation in tumor tissues. Our findings reveal a new explanation for the anti-tumor mechanisms of hispidulin, and suggest that SphK1 and ceramide may serve as potential therapeutic targets for the treatment of ccRCC.

Keywords: hispidulin; SphK1; ceramide; ROS/JNK signaling; apoptosis; clear-cell renal cell carcinoma

Acta Pharmacologica Sinica (2017) 38: 1618–1631; doi: 10.1038/aps.2017.154; published online 9 Nov 2017

Introduction

Renal cell carcinoma (RCC) is the 7th most common cancer in the developed world and is by far the most lethal urologic cancer, accounting for 80%–85% of kidney cancer cases[1]. There are approximately 209 000 new RCC cases and 102 000 related deaths per year worldwide[2]. Clear-cell renal cell carcinoma (ccRCC), the most common histological subtype of RCC, can be cured with partial or radical nephrectomy at an early stage. However, approximately 20%–30% of patients present with metastatic ccRCC at diagnosis. Moreover, up to 30% of newly diagnosed patients with localized disease develop metastases, and the recurrence rate is 20%–30% in patients after surgery[3]. During the past decade, a better understanding of ccRCC carcinogenesis has led to the development of novel therapeutics targeting two interacting pathways: the VHL/HIF/VEGF and PI3K/AKT/mTOR pathways; these strategies have improved the prognosis of patients with ccRCC[4-7]. Despite advances in diagnostic and therapeutic strategies, including the introduction of targeted therapy in clinical practice, clinical outcomes have unfortunately not shown a satisfactory improvement in the past decade, because of tumor recurrence and metastasis. Therefore, a better understanding of the factors involved in the tumorigenesis process of ccRCC is imperative to develop more effective therapeutic strategies.

A number of bioactive lipids, including ceramide (Cer), sphingosine (Sph), and sphingosine 1-phosphate (S1P), play a crucial role in the development and progression of human cancers by regulating cell proliferation, apoptosis, migration, senescence and responses to stressful conditions[8]. Among these lipids, ceramide has been identified as an anti-tumor effector that induces cell cycle arrest or apoptosis in cancerous cells[9]. In contrast, S1P functions as a pro-survival effector[10].

[#]These authors contributed equally to this work.

*To whom correspondence should be addressed.
E-mail jianjunpeng@126.com (Jian-jun PENG);
hanyt19@126.com (Yan-tao HAN)
Received 2017-05-15 Accepted 2017-07-09

The balance between ceramide and S1P is a key signal that determines cell fate, and sphingosine kinase 1 (SphK1) is an enzyme that plays a key role in the ceramide-S1P balance[10]. Aberrant overexpression of SphK1 has been observed in a wide variety of human cancers, and the association between SphK1 expression and prognosis has been established[11]. Regarding ccRCC, SphK1 is up-regulated in ccRCC patients and is correlated with clinical outcomes[12]. Our previous work has also shown that SphK1 is involved in acquired resistance to sunitinib in renal cell carcinoma cells[13]. These data suggest that SphK1 is a potential therapeutic target for treating ccRCC[14]. Hispidulin (4',5,7-trihydroxy-6-methoxyflavone), a polyphenolic flavonoid, has been extracted from the traditional Chinese medicinal plant *S involucrata*[15, 16] and has antifungal, anti-inflammatory, antioxidant, anti-thrombosis, antiepileptic, neuroprotective and antiosteoporotic activities[17-24]. Furthermore, hispidulin has also been identified to have an anti-proliferative effect on a wide variety of cancer cells, including pancreatic, gastric, ovarian and glioblastoma cells[25-28]. We have previously verified the pro-apoptotic effects of hispidulin in hepatocellular carcinoma cells and leukemia cells[29, 30]. However, the underlying mechanisms through which hispidulin exerts its anti-tumor effects are not fully understood. Therefore, the present study was conducted to determine whether hispidulin suppresses tumor growth in ccRCC. Our results showed that hispidulin inhibits SphK1 activity and induces the subsequent accumulation of ceramide in ccRCC cells. Moreover, our findings suggested that increased cellular ceramide levels lead to ROS generation and JNK activation, thus resulting in apoptosis.

Materials and methods

Cell culture

The human ccRCC cell lines Caki-2 and ACHN were purchased from the ATCC. HK-2 tubule epithelial cells were purchased from the Cell Bank of the Shanghai Institute of Biological Science (Shanghai, China). Cells were cultured at 37 °C in a humidified atmosphere with 5% CO_2 in DMEM medium (HyClone, Logan, UT, USA) with 10% (*v*/*v*) heat-inactivated FEB (HyClone, Logan, UT, USA), 2 mmol/L glutamine (Sigma, St Louis, MO, USA), [illegible]% nonessential amino acids (Sigma, St Louis, MO, USA) and 10[illegible] U/mL streptomycin and penicillin (Sigma, St Louis, MO, USA). Hispidulin was purchased from Sigma-Aldrich (St Louis, MO, USA).

Primary culture of human RCC cells

Primary cultures of human RCC cells were obtained from tissue specimens as previously described[31]. Tumor tissues were collected from 3 patients with ccRCC who received total nephroureterectomy at the Affiliated Hospital of Qingdao University (Qingdao, China). The baseline information of the 3 patients is listed in Table 1. The ccRCC tissues were minced and then digested with collagenase I (Sigma, St Louis, MO, USA). Cells were obtained by rinsing and filtering. Primary ccRCC cells were cultured in FBS-DMEM/F12 medium supplemented with 10 ng/mL basic fibroblast growth factor (bFGF) and 10 ng/mL epidermal growth factor (EGF)[32]. After 3 to 6 passages, primary ccRCC cells were used in our study. The study protocol was reviewed and approved by the Medical Ethics Committee of Qingdao University. Consent forms were signed by all participating patients.

Table 1. Clinicopathological features of 3 patients with primary ccRCC.

Patient No	Gender	Age	TNM stage	Lymph node metastasis
1	Male	54	II	N0
1	Female	61	II	N0
1	Male	51	I	N0

Cell counting kit-8 (CCK-8) assay

The cell viability was determined using a CCK-8 kit (Beyotime, Shanghai, China) according to the manufacturer's instructions. The optical density of viable cells was measured using a spectrophotometer (Tecan Group Ltd, Männedorf, Switzerland).

Flow cytometry analysis of apoptosis

Cell apoptosis was determined using a FITC Annexin V apoptosis kit (BD Pharmingen, Franklin Lakes, NJ, USA). Briefly, cells were harvested at a density of 5×10^5 cells/mL and incubated with Annexin V-FITC and propidium (PI) in the dark for 15 min before detection with a flow cytometer (Beckman Coulter Inc, Miami, FL, USA).

Measurement of mitochondrial membrane potential (MMP)

JC-1 staining was performed to assess changes in the MMP. Briefly, cells were stained with JC-1 and then collected as a cell pellet. Excess JC-1 was removed by rinsing the cell pellet with PBS. After resuspension, the fluorescence intensity of the cell solution was measured to determine the MMP.

Reactive oxygen species (ROS) assay

The fluorescent probe 2',7'-dichlorofluorescein-diacetate (DCFH-DA) was used to detect the ROS levels in ccRCC cells. After treatment, ccRCC cells were harvested and resuspended in DCFH-DA (10 μmol/L) at 37 °C for 30 min in the dark. Flow cytometry was used to quantify fluorescence signals, and the results were analyzed using Cell Quest software.

qRT-PCR analysis of Sphk1 expression

Total RNA was extracted from cultured cells by using TRIzol reagent (Thermo Fisher Scientific, Waltham, MA, USA). Briefly, cDNA was acquired using a High Capacity cDNA Archive Kit (Applied Biosystems, Foster City, CA, USA). The primers for SphK1 were synthesized on the basis of the published sequence[33]. First-strand cDNA was obtained using Super M-MLV Reverse transcriptase (BioTeke Co, Beijing, China). PCR reactions were performed using SYBR GREEN master mix (Solarbio Co, Beijing, China). GAPDH was used for normalizing SphK1 mRNA expression. The comparative ΔCt method (ABPrism software, Applied Biosystems, Foster

RETRACTED ARTICLE

City, CA, USA) was used to quantify PCR results.

Separation of the cytosolic and mitochondrial proteins

Cytosolic and mitochondrial fractions of proteins were separated as previously described[34]. After treatment, cells were resuspended in mitochondrial protein isolation buffer (Amresco, Solon, OH, USA) according to the manufacturer's protocol. The cytosolic and mitochondrial fractions of the proteins were collected for Western blotting.

Western blotting

Proteins were extracted from cells as previously described[30]. Specific primary antibodies against cleaved caspase-3, cleaved caspase-8, cleaved caspase-9, SphK1, cytochrome *c* and β-actin were purchased from Abcam (Shanghai, China), antibodies against Ki-67, p-JNK (Thr183/Tyr185), JNK, Fas, Fas-L, and FADD were from Santa Cruz Biotechnology (Santa Cruz, CA, USA), and the antibody against ceramide was from Sigma-Aldrich (St Louis, MO, USA). The secondary antibodies used in this study were goat anti-rabbit IgG-HRP or anti-mouse IgG-HRP (Beyotime, Shanghai, China). Signals were monitored using a chemiluminescent substrate (KPL, Guildford, UK).

Ceramide assay

The ceramide level was analyzed as previously described[35], and the results are presented as pmol per nmol of phospholipid (PL).

Analysis of sphingosine kinase 1 activity

The activity assay for sphingosine kinase was conducted with the Sphingosine Kinase Activity Assay Kit (Echelon Research Laboratories, Inc, Salt Lake City, UT, USA) according to the manufacturer's instructions. Briefly, cell lysate (20 μL) was incubated with the reaction buffer, 100 μmol/L sphingosine and 10 μmol/L ATP for 1 h at 37 °C, and a luminescence attached ATP detector was then added to stop the kinase reaction. Kinase activity was measured on the basis of the luminescence signals[13].

Analysis of sphingomyelinase (SMase), ceramide synthase, sphingomyelin synthase (SMS) and glucosylceramide synthase (GCS) activity

The activity of sphingomyelinase, ceramide synthase and glucosylceramide synthase was determined using NBD-sphingomyelin from Baijun Biotechnology (Guangzhou, China) as previously described[36, 37]. Briefly, cells (1×10^6) were lysed and incubated with 15 μmol/L NBD-sphingomyelin. The reaction was halted with chloroform/methanol (2:1, *v*:*v*), and the lipids were obtained by extraction. Lipids were separated with TLC silica gel plates. The fluorescence signal of NBD-ceramide (excitation/emission of 460/515 nm) was detected using a Typhoon 9410 variable mode imager (GE, Shanghai, China).

Enzyme activity assay for serine palmitoyltransferase (SPT)

Serine palmitoyltransferase activity was determined as previously described[37]. Briefly, cells were suspended in assay buffer and incubated at 37 °C for 1 h. The reaction was terminated with $NaBH_4$ (5 mg/mL). The activity of SPT was quantified by using an HPLC system with a fluorescence detector (Agilent, Santa Clara, CA, USA).

Interference vector construction and transfection

The siRNA oligos for SphK1 gene knockdown were designed and synthesized by Sangon (Shanghai, China) as previously described[13]. Two distinct siRNA sequences and one scrambled sequence for a control were cloned into the plasmid vector pGCsi-H1 according to the manufacturer's instructions. The ccRCC cells in the logarithmic growth phase were plated in 6-well plates at a density of 3×10^5 cells per well, and transfection was conducted using Lipofectamine 3000 (Invitrogen, Grand Island, NY, USA) according to the manufacturer's instructions.

SphK1 overexpression

SphK1 overexpressing and control vectors were constructed as previously described[13]. Transfection of the SphK1 overexpressing construct was performed using Lipofectamine 3000 (Invitrogen, Grand Island, NY, USA) according to the manufacturer's instructions.

Xenograft model

Eight week-old male athymic BALB/c nu/nu mice were maintained under pathogen-free conditions. Caki-2 cells (10^7 cells) were injected into the left flanks of mice. At 21 d after injection, mice were randomly allocated into three groups (8 mice per group) to receive intraperitoneal (IP) injections as follows: (A) vehicle (0.9% sodium chloride plus 1% DMSO), (B) hispidulin (20 mg·kg^{-1}·d^{-1}, dissolved in vehicle), (C) hispidulin (40 mg·kg^{-1}·d^{-1}, dissolved in vehicle daily). Mouse body weights and tumor volumes were measured twice per week. IHC staining and TUNEL assays were performed on cryostat sections (4 μm sections) of Caki-2 xenograft tumors; this protocol has been described in detail in our previous work[38]. Animal experiments for this study were approved by the Institutional Animal Care and Use Committee at Qingdao University.

Statistical analysis

Data are expressed as the mean±SD. Statistical comparisons between cell lines were analyzed by one-way ANOVA followed by Dunnett's *t*-test. Experimental data were analyzed with GraphPad Prism software (GraphPad Software Inc, La Jolla, CA, USA), and a *P* value less than 0.05 was considered statistically significant.

Results

Hispidulin inhibits cell growth in ccRCC cell lines and primary ccRCC cells

To explore the therapeutic potential of hispidulin in ccRCC cells, the anti-growth effect of hispidulin on cultured ccRCC cells was first examined. Figure 1A indicates that hispidulin suppressed the cell growth of both ccRCC cell lines, Caki-2

RETRACTED ARTICLE



Figure 1. Effects of hispidulin on cell survival. (A) Hispidulin inhibits the growth of both ccRCC cell lines, Caki-2 and ACHN. Cells were treated with the indicated concentration of hispidulin for 24 h, 48 h, and 72 h. (B) Viability of the primary ccRCC cells and the normal tubular epithelial cells after hispidulin treatment was measured. Cell viability was analyzed by CCK-8 assay. $^{**}P<0.01$.

RETRACTED ARTICLE

and ACHN, in a time- and concentration-dependent manner. The effects of hispidulin on the cell growth of primary ccRCC cells were also examined. As shown in Figure 1B, hispidulin treatment also dose-dependently decreased the viability of primary ccRCC cells. Notably, hispidulin did not decrease survival of HK-2 cells, the normal tubular epithelial cells (Figure 1B). Taken together, our results suggested that hispidulin selectively exerted anti-growth effects against ccRCC cells without harming healthy kidney cells.

Hispidulin induces apoptosis in ccRCC cells

To investigate the underlying mechanisms of the growth-inhibition by hispidulin, cell apoptosis was analyzed. Following treatment of hispidulin, both Caki-2 and ACHN cells exhibited dose-dependent increases in the number of apoptotic cells (Figure 2A). Because activation of caspases plays a crucial role in apoptotic cell death, specific inhibitors of caspase-3 (z-VAD-FMK), caspase-8 (z-LEHD-FMK) and caspase-9 (z-IETD-FMK) were used to explore the involvement of caspase activation in hispidulin-induced apoptosis. As shown in Figure 2B and 2C, hispidulin treatment resulted in marked elevation in level of cleaved caspase-3 and caspase-3 inhibitors completely abolished the hispidulin-induced apoptosis, thus suggesting that hispidulin mediated caspase-dependent apoptosis in ccRCC cells. Moreover, our findings demonstrated that pretreatment with either the caspase-8 inhibitor or the caspase-9 inhibitor partly blocked hispidulin-induced apoptosis (Figure 2B). The Western blot results also confirmed that hispidulin increased the levels of both cleaved caspase-8 and cleaved caspase-9 (Figure 2C). Given the roles of caspase-8 and caspase-9 in extrinsic and intrinsic apoptotic signaling pathways, respectively, our results suggested that hispidulin triggers apoptosis via both pathways. To further demonstrate the effects of hispidulin on the extrinsic pathway, the effects of hispidulin on the expression of proteins relevant to the Fas death receptor pathway were also examined. Although hispidulin did not affect the expression level of TNFR1 in both types of ccRCC cells, dose-dependent activation of Fas/FasL signaling and DR5 were found after hispidulin treatment (Figure 3A). Intrinsic apoptosis is characterized by the translocation of cytochrome *c* from mitochondria to the cytosol and by disruption of the MMP. As shown in Figure 3B and 3C, hispidulin treatment led to disruption of the MMP and the loss of cytochrome *c* from mitochondria. Our findings confirmed that both extrinsic and intrinsic pathways are involved in hispidulin-induced apoptosis in Caki-2 and ACHN cells.

Hispidulin-induced apoptosis is associated with ceramide accumulation and inhibition of SphK1 activity

Ceramide is a pro-apoptotic bioactive sphingolipid, and accumulating evidence has shown that the accumulation of ceramide triggers apoptosis signaling in cancerous cells[8]. Therefore, we investigated the effects of hispidulin on the levels of ceramide in Caki-2 and ACHN cells. As shown in Figure 4A, hispidulin treatment for 48 h led to a marked increase in ceramide levels in both cell types by promoting ceramide gen-



Figure 2. Pro-apoptotic effects of hispidulin on ccRCC cell lines. (A) Hispidulin promotes cell apoptosis in Caki-2 and ACHN cells as measured by flow cytometry. (B) Hispidulin-induced cell apoptosis is significantly abrogated by specific inhibitors of caspase-3 (z-VAD-FMK), caspase-8 (z-LEHD-FMK), and caspase-9 (z-IETD-FMK) as measured by flow cytometry. (C) The expression of cleaved caspase-3, cleaved caspase-8, and cleaved caspase-9 were increased by hispidulin as analyzed by Western blotting. $^{**}P<0.01$.

RETRACTED ARTICLE

eration or suppressing its metabolism. Therefore, whether hispidulin can affect the activity of enzymes related to ceramide generation and metabolism was examined. In cancer cells, intracellular ceramide levels can be increased via *de novo* synthesis or sphingomyelin hydrolysis. As shown in Figure 4B, hispidulin did not significantly alter the activity of SPT and ceramide synthase, two enzymes mediating the *de novo* synthesis of ceramide, or neutral and acid SMases, two enzymes mediating sphingomyelin hydrolysis, thereby indicating that the ceramide accumulation resulting from hispidulin treatment was not due to excessive generation. Interestingly, hispidulin significantly suppressed the activity of SphK1, although no significant effects on the activity of SMS and GCS were found (Figure 4C). Furthermore, our results showed that hispidulin did not affect the mRNA or protein expression of SphK1 (Figure 4D). Collectively, our findings suggested that



Figure 3. Hispidulin induces extrinsic and intrinsic apoptosis in Caki-2 and ACHN cells. (A) Hispidulin activates Fas/FasL signaling and DR5 but does not affect the expression of TNFR1 as determined by Western blotting. (B) Hispidulin releases cytochrome *c* from mitochondria to the cytoplasm as determined by Western blotting. (C) Hispidulin causes the loss of MMP as measured by flow cytometry. $^{**}P<0.01$.



Figure 4. Hispidulin induces ceramide accumulation by inhibiting Sphk1 activity. (A) Effects of hispidulin on the accumulation of ceramide. (B) Effects of hispidulin on enzyme activity involved in ceramide generation. (C) Effects of hispidulin on the activity of SMS, GCS, and SphK1. (D) qRT-PCR and Western blots measuring the mRNA and protein expression of SphK1 after hispidulin treatment. ***P*<0.01.

RETRACTED ARTICLE

hispidulin induces apoptosis through ceramide accumulation via inhibiting SphK1 activity.

Inhibition of SphK1 activity mediates the pro-apoptotic effect of hispidulin

Our results showed that hispidulin promoted ceramide accumulation via inhibiting SphK1 activity, leading to apoptosis. Next, we investigated whether inhibition of SphK1 activity mediated hispidulin-induced apoptosis in ccRCC cells. The off-target effect of hispidulin was demonstrated by SphK1 silencing. As shown in Figure 5A, the expression of SphK1 was decreased by more than 70% by RNA interference in both cell types. Then, the effects of hispidulin on cell growth and apoptosis were examined. Figure 5B and 5C show that hispidulin further augment SphK1 knockdown-induced growth inhibition and apoptosis. Moreover, an established pharmacological inhibitor of SphK1 exerted an additive effect with hispidulin in suppressing cell growth and inducing apoptosis



Figure 5. Repressing SphK1 expression or inhibiting SphK1 activity enhances the anti-growth and proapoptotic effects of hispidulin. (A) Western blots showing the protein expression levels of SphK1 in both Caki-2 and ACHN cells after siRNA transfection. (B) Effects of hispidulin on cell survival after siRNA transfection or pretreatment with a SphK1 inhibitor. (C) Effect of hispidulin on cell apoptosis after SphK1 knockdown or pretreatment with a SphK1 inhibitor as examined by flow cytometry. (D) Effect of hispidulin on the expression of cleaved caspase-3 after SphK1 knockdown or pretreatment with a Sphk1 inhibitor. ***P*<0.01.

RETRACTED ARTICLE



Figure 6. Overexpression of SphK1 or pretreatment with a SphK1 activator abolishes the anti-growth and proapoptotic effects of hispidulin A. Hispidulin exhibits anti-growth and pro-apoptotic effects by inhibiting SphK1 activity. Transfection of the SphK1-overexpressing plasmid and confirmation of the overexpression of SphK1 in Caki-2 and ACHN cells. The anti-proliferative effects of hispidulin were measured with a CCK-8 assay after Sphk1 overexpression or pretreatment with K6PC-5, an activator of Sphk1. (C) The pro-apoptotic effects of hispidulin with SphK1 overexpression or pretreatment with a SphK1 activator were assessed by flow cytometry. (D) The effects of hispidulin on the expression of cleaved caspase-3 after SphK1 overexpression or pretreatment with a SphK1 activator were detected by Western blotting. $^{**}P<0.01$.

(Figure 5B, 5C and 5D). Moreover, to further verify the crucial contribution of inhibition of SphK1 activity in the pro-apoptotic effect of hispidulin, SphK1 was overexpressed in Caki-2 and ACHN cells (Figure 6A). CCK-8 assay showed that the anti-proliferative effect of hispidulin was significantly compromised in SphK1 overexpressing ccRCC cells (Figure 6B). Correspondingly, flow cytometric analysis and Western blot also indicated that hispidulin-induced apoptosis and caspase-3 activation were significantly attenuated by ectopic overexpression of SphK1 (Figure 6C and 6D). Our findings also revealed that pretreatment with K6PC-5, a SphK1 activator, significantly reversed the anti-growth and apoptosis induction effects of hispidulin. Our findings indicated that hispidulin-induced apoptosis is mediated by its inhibitory effects on SphK1 activity.

Accumulation of ceramide activates ROS/JNK signaling and induces apoptosis

A recent study has shown that ROS/JNK signaling is associated with ceramide-induced apoptosis in cancer cells[39]. Our



Figure 7. Hispidulin promotes ROS generation and JNK activation. (A) ROS generation after treatment of Caki-2 and ACHN cells with hispidulin or hispidulin combined with K6PC-5, a Sphk1 activator. (B) The phosphorylation levels of JKN1/2 were detected by Western blotting after treatment with hispidulin or hispidulin combined with the ROS inhibitor NAC. (C) Cell apoptosis was examined by flow cytometry after treatment with hispidulin or hispidulin combined with NAC or the JNK inhibitor SP600125. (D) The expression of cleaved caspase-3 following treatment with hispidulin or hispidulin combined with NAC or the JNK inhibitor SP600125 weas detected by Western blotting. $^{**}P<0.01$.

RETRACTED ARTICLE

findings also verified that hispidulin administration was associated with a dose-dependent increase in intracellular ROS (Figure 7A), and this effect was markedly abrogated by K6PC-5, thus suggesting that the increases in the ROS level depended on SphK1 inhibition and subsequent ceramide accumulation. Western blots also showed that hispidulin induced JNK activation in a ROS-dependent manner (Figure 7B). Therefore, we next explored the role of ROS/JNK signaling in hispidulin-induced apoptosis by using the ROS inhibitor NAC and the JNK inhibitor SP600125. As shown in Figure 7C and 7D, neither NAC nor SP600125 abolished hispidulin-induced apoptosis in Caki-2 and ACHN cells. Our findings collectively indicated that hispidulin inhibits SphK1 activity and subsequently induces the accumulation of ceramide, which then activates ROS/JNK signaling and leads to apoptosis.

Hispidulin induces apoptosis *in vivo*

On the basis of our *in vitro* results, a xenograft mouse model was used to test the *in vivo* therapeutic effects of hispidulin. The dosages of hispidulin were 40 mg·kg^{-1}·d^{-1} and 20



Figure 8. Anti-neoplastic activity of hispidulin in Caki-2 xenograft tumors. (A) Measurements of tumor volume at the indicated time point after treatment with hispidulin (20 mg/kg or 40 mg/kg). (B) Effect of hispidulin on SphK1 activity *in vivo*. (C) TUNEL and immunohischemistry assay performed on cryostat sections were used to detect cell apoptosis and the expression of Ki-67, ceramide, cleaved caspase-3, and p-JNK1/2 after hispidulin treatment. $^{**}P<0.01$.

RETRACTED ARTICLE

mg·kg^{-1}·d^{-1}. As shown in Figure 8A, both dosages significantly suppressed tumor growth ($P<0.01$ *vs* control). Corresponding to our observation of tumor growth, TUNEL and immunohistochemistry assays showed that hispidulin treatment was associated with dose-dependent increases in cell apoptosis, as well as increases in the expression of cleaved caspase-3 (Figure 8C). Moreover, our results showed that tumor growth inhibition by hispidulin was correlated with decreased activity of SphK1, ceramide accumulation and increased expression of p-JNK in tissues (Figure 8B and 8C), thus supporting our *in vitro* findings that hispidulin mediates apoptosis in ccRCC by inhibiting SphK1 and consequently inducing ceramide accumulation, which in turn activates ROS/JNK signaling.

Discussion

Hispidulin has been used as an antifungal and anti-inflammatory agent in China for centuries[16]. The anti-neoplastic activity of hispidulin, a flavonoid compound, has also been documented[25, 27, 29, 40-42]. The role of hispidulin as a chemopreventive agent was first reported in 1992[43]. In 2010, Way *et al* revealed that hispidulin induces apoptosis in ovarian cancer and glioblastoma multiforme cells through activating AMPK signaling[25, 26]. Hispidulin also has been found to exerts its pro-apoptotic effects in a panel of cancerous cells, including gastric cancer cells, pancreatic cancer cells and hepatoma cells[28, 44, 45]. Moreover, our previous study has also demonstrated that hispidulin inhibits cell proliferation and induces apoptosis *in vitro* in hepatocellular carcinoma and gallbladder cancer[29, 41]. Our recent work has revealed that hispidulin induces mitochondrial apoptosis in leukemia cells, in addition to solid tumors[30]. Here, we explored the role of hispidulin in ccRCC and elucidated its potential molecular mechanisms. Our findings suggested that hispidulin inhibits SphK1 activity and induces the subsequent accumulation of ceramide, which in turn activates ROS/JNK signaling and eventually leads to apoptosis in ccRCC cells (Figure 9).

Apoptosis has been considered as the main pathway through which chemotherapeutics eradicate cancer cells[46]. Our findings in this study also showed that the *in vitro* antiproliferative effects and the *in vivo* tumor suppressing effects of hispidulin correlated with its pro-apoptotic effects, thus suggesting that hispidulin exerts its anti-tumor effects at least partly by inducing apoptosis. Apoptosis mainly occurs through two distinct pathways, the extrinsic or death receptor pathway and the intrinsic or mitochondrial pathway[47]. Both pathways involve the activation of initiator caspases, caspase-8



Figure 9. Proposed signal transduction pathways through which hispidulin induces apoptosis in ccRCC cells.

in the extrinsic pathway and caspase-9 in the intrinsic pathway; this process is followed by the activation of effector caspases, such as caspase-3, as apoptosis executioners[47]. Herein, we verified that the apoptosis induced by hispidulin in ccRCC cells occurred via both extrinsic and intrinsic pathways. The activation of the extrinsic apoptosis pathway by hispidulin was confirmed by caspase-8 activation and the increased expression of Fas protein levels in cells, whereas activation of the intrinsic apoptosis pathway by hispidulin was identified by the activation of caspase-9, disruption of the MMP, and cytochrome *c* release from mitochondria to the cytosol. The results of the present study are consistent with Way's results showing that hispidulin activates both the intrinsic and extrinsic apoptosis pathways by inducing p53 expression in human glioblastoma multiforme cells[26]. However, our previous studies using leukemia and hepatocellular carcinoma cells have shown that hispidulin induces apoptosis via only the mitochondrial pathway, a result also in line with Yu's findings in gastric cancer cells[28-30]. We postulate that the mechanism through which hispidulin induces apoptosis might depend on the major molecules or signaling pathway that contributes to the pro-apoptotic effects of hispidulin in specific cancerous cells. However, more data need to be collected to confirm our postulation.

The balance of ceramide-sphingosine-S1P rheostat has been identified to play a crucial role in deciding the fate of cancer cells[9]. In cancer cells, cellular ceramide accumulation correlates with anti-growth pathways, such as senescence and apoptosis[9]. Therefore, ceramide is considered a "tumor suppressor lipid". Cancer cells produce ceramide through *de novo* synthesis from palmitoyl-CoA and L-serine by using serine palmitoyl transferase (SPT) and ceramide synthase or through sphingomyelin hydrolysis by using sphingomyelinases (SMase)[9]. However, cellular ceramides are consumed for the production of sphingomyelin, glucosylceramide, or ceramide 1-phosphate through the actions of sphingomyelin synthase (SMS), glucosylceramide synthase (GCS), or SphK1, respectively[48]. A number of chemotherapeutic agents, including natural compounds, have been proposed to induce apoptosis in cancerous cells through ceramide accumulation by either promoting the *de novo* synthesis of ceramide or suppressing the metabolism of ceramide via targeting the above mentioned enzymes. An early study has reported that resveratrol, a phytoalexin present in grapes and red wine, inhibits cell proliferation and pro-apoptosis in metastatic breast cancer cells via *de novo* ceramide signaling via the activation of SPT[49]. Resveratrol has been found to increase the intracellular generation and accumulation of apoptotic ceramides through down-regulating GCS and SphK1[50]. Stichoposide C, a marine triterpene glycoside, was found to induce apoptosis in leukemia and colorectal cancer cells through ceramide generation via activating SMase[51]. Sobota *et al* have demonstrated that curcumin induces apoptosis in multidrug-resistant human leukemia HL60 cells by activating neutral sphingomyelinase (nSMase), after the inhibition of sphingomyelin synthase[36]. In our study, we found that ceramide accumulation is involved in hispidulin-induced apoptosis in ccRCC cells. Moreover, our findings indicated that hispidulin does not affect the generation of ceramide, but it suppresses the consumption of ceramide by inhibiting SphK1.

The dysregulation of SphK1 has been documented in a variety of human malignancies, and both preclinical and clinical evidence has shown that SphK1 is related to various cancer processes, such as cell oncogenesis, survival, metastasis and tumor microenvironment neovascuelarization[52], thus making SphK1 a promising therapeutic target[11]. In fact, SphK1 inhibitors are under evaluation in pre-clinical and clinical studies for their therapeutic effects[11]. Regarding ccRCC, fingolimod, a functional antagonist of the S1P receptor and an inhibitor of SphK1, chemosensitizes and promotes vascular remodeling in ccRCC[53]. In line with this recent finding, our results revealed that hispidulin induces apoptosis mainly by inhibiting SphK1 activity, thus suggesting that modulating SphK1 activity may provide a novel therapeutic strategy for ccRCC treatment.

In summary, our findings in the current study showed that hispidulin exerts a potent anti-neoplastic effect in ccRCC by inducing apoptosis. Furthermore, our findings also suggested that hispidulin inhibits SphK1 activity and consequently induces ceramide accumulation, thus resulting in apoptosis through activation of ROS/JNK signaling.

Acknowledgements

This work was supported by the National Natural Science Foundation of China (No 31470570 and 81603337), the Chongqing Natural Science Foundation (No cstc2014jcyjA80013), the Science Foundation of Chongqing Educa-

RETRACTED ARTICLE

tion Commission (No kj1400534), and the Project of Clinical Medicine+X, Department of Medicine, Qingdao University (2017M38).

References

1 Jemal A, Bray F, Center MM, Ferlay J, Ward E, Forman D. Global cancer statistics. CA Cancer J Clin 2011; 61: 69–90.
2 Rini BI, Campbell SC, Escudier B. Renal cell carcinoma. Lancet 2009; 373: 1119–32.
3 Antonelli A, Cozzoli A, Zani D, Zanotelli T, Nicolai M, Cunico SC, *et al*. The follow-up management of non-metastatic renal cell carcinoma: definition of a surveillance protocol. BJU Int 2007; 99: 296–300.
4 Escudier B, Eisen T, Stadler WM, Szczylik C, Oudard S, Siebels M, *et al*. Sorafenib in advanced clear-cell renal-cell carcinoma. New Engl J Med 2007; 356: 125–34.
5 Hudes G, Carducci M, Tomczak P, Dutcher J, Figlin R, Kapoor A, *et al*. Temsirolimus, interferon alfa, or both for advanced renal-cell carcinoma. New Engl J Med 2007; 356: 2271–81.
6 Motzer RJ, Hutson TE, Tomczak P, Michaelson MD, Bukowski RM, Rixe O, *et al*. Sunitinib versus interferon alfa in metastatic renal-cell carcinoma. New Engl J Med 2007; 356: 115–24.
7 Motzer RJ, Escudier B, Oudard S, Hutson TE, Porta C, Bracarda S, *et al*. Efficacy of everolimus in advanced renal cell carcinoma: a double-blind, randomised, placebo-controlled phase III trial. Lancet 2008; 372: 449–56.
8 Adan-Gokbulut A, Kartal-Yandim M, Iskender G, Baran Y. Novel agents targeting bioactive sphingolipids for the treatment of cancer. Curr Med Chem 2013; 20: 108–22.
9 Cuvillier O, Ader I, Bouquerel P, Brizuela L, Malavaud B, Mazerolles C, *et al*. Activation of sphingosine kinase-1 in cancer: implications for therapeutic targeting. Curr Mol Pharmacol 2010; 3: 53–65.
10 Maceyka M, Harikumar KB, Milstien S, Spiegel S. Sphingosine-1-phosphate signaling and its role in disease. Trends Cell Biol 2012; 22: 50–60.
11 Zhang Y, Wang Y, Wan Z, Liu S, Cao Y, Zeng Z. Sphingosine kinase 1 and cancer: a systematic review and meta-analysis. PLoS One 2014; 9: e90362.
12 Salama MF, Carroll B, Adada M, Pulkoski-Gross M, Hannun YA, Obeid LM. A novel role of sphingosine kinase-1 in the invasion and angiogenesis of VHL mutant clear cell renal cell carcinoma. FASEB J 2015; 29: 2803–13.
13 Gao H, Deng L. Sphingosine kinase-1 activation causes acquired resistance against Sunitinib in renal cell carcinoma cells. Cell Biochem Biophys 2014; 68: 419–25.
14 Alshaker H, Sauer L, Monteil D, Ottaviani S, Srivats S, Bohler T, *et al*. Therapeutic potential of targeting SK1 in human cancers. Adv Cancer Res 2013; 117: 143–200.
15 Way TD, Lee JC, Kuo DH, Fan LL, Huang CH, Lin HY, *et al*. Inhibition of epidermal growth factor receptor signaling by *Saussurea involucrata*, a rare traditional Chinese medicinal herb, in human hormone-resistant prostate cancer PC-3 cells. J Agric Food Chem 2010; 58: 3356–65.
16 Yin Y, Gong FY, Wu XX, Sun Y, Li YH, Chen T, *et al*. Anti-inflammatory and immunosuppressive effect of flavones isolated from *Artemisia vestita*. J Ethnopharmacol 2008; 120: 1–6.
17 Kavvadias D, Sand P, Youdim KA, Qaiser MZ, Rice-Evans C, Baur R, *et al*. The flavone hispidulin, a benzodiazepine receptor ligand with positive allosteric properties, traverses the blood-brain barrier and exhibits anticonvulsive effects. Br J Pharmacol 2004; 142: 811–20.
18 Tan RX, Lu H, Wolfender JL, Yu TT, Zheng WF, Yang L, *et al*. Mono- and sesquiterpenes and antifungal constituents from *Artemisia species*. Planta Medica 1999; 65: 64–7.
19 Nagao T, Abe F, Kinjo J, Okabe H. Antiproliferative constituents in plants 10. Flavones from the leaves of *Lantana montevidensis* Briq and consideration of structure-activity relationship. Biol Pharm Bull 2002; 25: 875–9.
20 Chen YT, Zheng RL, Jia ZJ, Ju Y. Flavonoids as superoxide scavengers and antioxidants. Free Radic Biol Med 1990; 9: 19–21.
21 Bourdillat B, Delautier D, Labat C, Benveniste J, Potier P, Brink C. Mechanism of action of hispidulin, a natural flavone, on human platelets. Prog Clin Biol Res 1988; 280: 211–4.
22 Niu X, Chen J, Wang P, Zhou H, Li S, Zhang M. The effects of hispidulin on bupivacaine-induced neurotoxicity: role of AMPK signaling pathway. Cell Biochem Biophys 2014; 70: 241–9.
23 Zhou R, Wang Z, Ma C. Hispidulin exerts anti-osteoporotic activity in ovariectomized mice via activating AMPK signaling pathway. Cell Biochem Biophys 2014; 69: 311–7.
24 Nepal M, Choi HJ, Choi BY, Yang MS, Chae JI, Li L, *et al*. Hispidulin attenuates bone resorption and osteoclastogenesis via the RANKL-induced NF-kappaB and NFATc1 pathways. Eur J Pharmacol 2013; 715: 96–104.
25 Yang JM, Hung CM, Fu CN, Lee JC, Huang CH, Yang MH, *et al*. Hispidulin sensitizes human ovarian cancer cells to TRAIL-induced apoptosis by AMPK activation leading to Mcl-1 block in translation. J Agric Food Chem 2010; 58: 10020–6.
26 Lin YC, Hung CM, Tsai JC, Lee JC, Chen YL, Wei CW, *et al*. Hispidulin potently inhibits human glioblastoma multiforme cells through activation of AMP-activated protein kinase (AMPK). J Agric Food Chem 2010; 58: 9511–7.
27 He L, Wu Y, Lin L, Wang J, Chen Y, Yi Z, *et al*. Hispidulin, a small flavonoid molecule, suppresses the angiogenesis and growth of human pancreatic cancer by targeting vascular endothelial growth factor receptor 2-mediated PI3K/Akt/mTOR signaling pathway. Cancer Sci 2011; 102: 219–25.
28 Yu CY, Su KY, Lee PL, Jhan JY, Tsao PH, Chan DC, *et al*. Potential therapeutic role of hispidulin in gastric cancer through induction of apoptosis via NAG-1 signaling. Evid Based Complement Alternat Med 2013; 2013: 518301.
29 Gao H, Wang H, Peng J. Hispidulin induces apoptosis through mitochondrial dysfunction and inhibition of P13k/Akt signalling pathway in HepG2 cancer cells. Cell Biochem Biophys 2014; 69: 27–34.
30 Gao H, Liu Y, Li K, Wu T, Peng J, Jing F. Hispidulin induces mitochondrial apoptosis in acute myeloid leukemia cells by targeting extracellular matrix metalloproteinase inducer. Am J Transl Res 2016; 8: 1115–32.
31 Zheng B, Mao JH, Li XQ, Qian L, Zhu H, Gu DH, *et al*. Over-expression of DNA-PKcs in renal cell carcinoma regulates mTORC2 activation, HIF-2alpha expression and cell proliferation. Sci Rep 2016; 6: 29415.
32 Pan XD, Gu DH, Mao JH, Zhu H, Chen X, Zheng B, *et al*. Concurrent inhibition of mTORC1 and mTORC2 by WYE-687 inhibits renal cell carcinoma cell growth *in vitro* and *in vivo*. PLoS One 2017; 12: e0172555.
33 Liu SQ, Su YJ, Qin MB, Mao YB, Huang JA, Tang GD. Sphingosine kinase 1 promotes tumor progression and confers malignancy phenotypes of colon cancer by regulating the focal adhesion kinase pathway and adhesion molecules. Int J Oncol 2013; 42: 617–26.
34 Lee CJ, Han JS, Seo CY, Park TH, Kwon HC, Jeong JS, *et al*. Pioglitazone, a synthetic ligand for PPARgamma, induces apoptosis in RB-deficient human colorectal cancer cells. Apoptosis 2006; 11: 401–11.
35 Yao C, Wu S, Li D, Ding H, Wang Z, Yang Y, *et al*. Co-administration

RETRACTED ARTICLE

phenoxodiol with doxorubicin synergistically inhibit the activity of sphingosine kinase-1 (SphK1), a potential oncogene of osteosarcoma, to suppress osteosarcoma cell growth both *in vivo* and *in vitro*. Mol Oncol 2012; 6: 392–404.

36 Shakor AB, Atia M, Ismail IA, Alshehri A, El-Refaey H, Kwiatkowska K, *et al*. Curcumin induces apoptosis of multidrug-resistant human leukemia HL60 cells by complex pathways leading to ceramide accumulation. Biochim Biophys Acta 2014; 1841: 1672–82.

37 Kim KP, Shin KO, Park K, Yun HJ, Mann S, Lee YM, *et al*. Vitamin C stimulates epidermal ceramide production by regulating its metabolic enzymes. Biomol Ther (Seoul) 2015; 23: 525–30.

38 Han Y, Yang X, Zhao N, Peng J, Gao H, Qiu X. Alpinumisoflavone induces apoptosis in esophageal squamous cell carcinoma by modulating miR-370/PIM1 signaling. Am J Cancer Res 2016; 6: 2755–71.

39 Chen L, Ren J, Yang L, Li Y, Fu J, Li Y, *et al*. Stearoyl-CoA desaturase-1 mediated cell apoptosis in colorectal cancer by promoting ceramide synthesis. Sci Rep 2016; 6: 19665.

40 Wang Y, Liu W, He X, Fei Z. Hispidulin enhances the anti-tumor effects of temozolomide in glioblastoma by activating AMPK. Cell Biochem Biophys 2015; 71: 701–6.

41 Gao H, Xie J, Peng J, Han Y, Jiang Q, Han M, *et al*. Hispidulin inhibits proliferation and enhances chemosensitivity of gallbladder cancer cells by targeting HIF-1alpha. Exp Cell Res 2015; 332: 236–46.

42 Gao H, Jiang Q, Han Y, Peng J, Wang C. Hispidulin potentiates the antitumor effect of sunitinib against human renal cell carcinoma in laboratory models. Cell Biochem Biophys 2015; 71: 757–64.

43 Liu YL, Ho DK, Cassady JM, Cook VM, Baird WM. Isolation of potential cancer chemopreventive agents from *Eriodictyon californicum*. J Nat Prod 1992; 55: 357–63.

44 Scoparo CT, Valdameri G, Worfel PR, Guterres FA, Martinez GR, Winnischofer SM, *et al*. Dual properties of hispidulin: antiproliferative effects on HepG2 cancer cells and selective inhibition of ABCG2 transport activity. Mol Cell Biochem 2015; 409: 123–33.

45 Wu J, Ru NY, Zhang Y, Li Y, Wei D, Ren Z, *et al*. HAb18G/CD147 promotes epithelial-mesenchymal transition through TGF-beta signaling and is transcriptionally regulated by Slug. Oncogene 2011; 30: 4410–27.

46 Safarzadeh E, Sandoghchian Shotorbani S, Baradaran B. Herbal medicine as inducers of apoptosis in cancer treatment. Adv Pharm Bull 2014; 4: 421–7.

47 Dias N, Bailly C. Drugs targeting mitochondrial functions to control tumor cell growth. Biochem Pharmacol 2005; 70: 1–12.

48 Mullen TD, Obeid LM. Ceramide and apoptosis: exploring the enigmatic connections between sphingolipid metabolism and programmed cell death. Anticancer Agents Med Chem 2012; 12: 340–63.

49 Scarlatti F, Sala G, Somenzi G, Signorelli P, Sacchi N, Ghidoni R. Resveratrol induces growth inhibition and apoptosis in metastatic breast cancer cells via *de novo* ceramide signaling. FASEB J 2003; 17: 2339–41.

50 Kartal M, Saydam G, Sahin F, Baran Y. Resveratrol triggers apoptosis through regulating ceramide metabolizing genes in human K562 chronic myeloid leukemia cells. Nutr Cancer 2011; 63: 637–44.

51 Yun SH, Park ES, Shin SW, Na YW, Han JY, Jeong JS, *et al*. Stichoposide C induces apoptosis through the generation of ceramide in leukemia and colorectal cancer cells and shows *in vivo* antitumor activity. Clin Cancer Res 2012; 18: 5934–48.

52 Pyne NJ, Tonelli F, Lim KG, Long JS, Edwards J, Pyne S. Sphingosine 1-phosphate signalling in cancer. Biochem Soc Trans 2012; 40: 94–100.

53 Gstalder C, Ader I, Cuvillier O. FTY720 (Fingolimod) inhibits HIF1 and HIF2 signaling, promotes vascular remodeling, and chemosensitizes in renal cell carcinoma animal model. Mol Cancer Ther 2016; 15: 2465–74.

RETRACTED ARTICLE